⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
ABBOTINDIA - Swing Trade Analysis with AI Signals
Last Updated Time : 05 Nov 25, 7:43 am
Back to Swing Trade List✅ Swing Trade Rating: 3.2
Entry Zone: ₹28,500–₹29,000 (only if RSI > 45 and MACD flattens)
Exit if held: ₹30,400–₹30,600 (near 50 DMA and resistance zone)
📊 Technical & Fundamental Snapshot
- 📉 Current Price: ₹29,400
- 📉 52W High/Low: ₹37,000 / ₹25,260
- 📉 RSI: 39.2 (weak momentum)
- 📉 MACD: -325 (bearish crossover)
- 📈 Volume: 8.7K vs 1W Avg 8.1K (stable)
- 📉 DII Holding Change: -0.07%
- 📈 FII Holding Change: 0.00% (neutral)
- 📈 Qtr Profit Growth: +11.5%
- 📈 PEG Ratio: 2.05 (growth priced in)
- 📈 P/E: 43.0 vs Industry 33.1 (premium valuation)
✅ Positive
- 📈 ROCE & ROE: 46.2% and 35.7% — elite capital efficiency.
- 📉 Low Debt: Debt-to-equity at 0.05 — near debt-free.
- 📈 EPS: ₹683 — strong earnings base.
- 📈 Dividend Yield: 1.62% — modest income support.
- 📈 Stable PAT: ₹366 Cr vs ₹367 Cr QoQ — consistent profitability.
⚠️ Limitation
- 📉 RSI Below 40: Indicates weak momentum and possible oversold zone.
- 📉 MACD Deep Negative: Suggests bearish trend continuation.
- 📉 Below DMA 50 & 200: Price under key moving averages.
- 📉 Valuation Risk: P/E of 43 — ~30% above industry average.
🚨 Company Negative News
- 📉 Management Turnover: Resignation of senior personnel announced in Sep 2025
The Economic Times
.
- 📉 Technical Downgrade: Trendlyne flagged bearish monthly trend despite stable fundamentals
Trendlyne
.
📈 Company Positive News
- 🚀 Analyst Optimism: Forecasts indicate sustained EPS and revenue growth amid strong pharma demand
markets.financialcontent.com
.
- 📈 Valuation Target: Average analyst target at ₹35,337 — ~20% upside from current price
Trendlyne
.
- 📦 Regulatory Compliance: SEBI filings confirm operational integrity and transparency
The Economic Times
.
💊 Industry
- 📈 Pharma Expansion: Indian healthcare market growing rapidly with increased demand for branded generics.
- 📉 Margin Pressure: Sector facing cost inflation and regulatory headwinds in pricing.
🧾 Conclusion
- ⚠️ Not ideal for fresh swing entry unless RSI > 45 and MACD flattens with volume confirmation.
- 📤 If already held, exit near ₹30,400–₹30,600 (DMA resistance zone).
- 📈 Fundamentals strong, technicals weak — suitable for cautious trailing stop strategy with alert logic.
Sources
The Economic Times
Economic Times – Abbott India updates
markets.financialcontent.com
MarketMinute – Abbott India forecast
Trendlyne
Trendlyne – Analyst reports
Back to Swing Trade ListNIFTY 50 - Today Top Swing Trade Stock Picks
NEXT 50 - Today Top Swing Trade Stock Picks
MIDCAP - Today Top Swing Trade Stock Picks
SMALLCAP - Today Top Swing Trade Stock Picks